Cargando…
The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
BACKGROUND: The genome map of hepatocellular carcinoma (HCC) is complex. In order to explore whether circulating tumor cell DNA (ctDNA) can be used as the basis for sequencing and use ctDNA to find tumor related biomarkers, we analyzed the mutant genes of ctDNA in patients with liver cancer by seque...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121877/ https://www.ncbi.nlm.nih.gov/pubmed/35602894 http://dx.doi.org/10.7717/peerj.13473 |
_version_ | 1784711235439165440 |
---|---|
author | Ding, Yubo Yao, Jingwei Wen, Meiling Liu, Xiong Huang, Jialu Zhang, Minghui Zhang, Yu Lv, Yufan Xie, Zhuoyi Zuo, JianHong |
author_facet | Ding, Yubo Yao, Jingwei Wen, Meiling Liu, Xiong Huang, Jialu Zhang, Minghui Zhang, Yu Lv, Yufan Xie, Zhuoyi Zuo, JianHong |
author_sort | Ding, Yubo |
collection | PubMed |
description | BACKGROUND: The genome map of hepatocellular carcinoma (HCC) is complex. In order to explore whether circulating tumor cell DNA (ctDNA) can be used as the basis for sequencing and use ctDNA to find tumor related biomarkers, we analyzed the mutant genes of ctDNA in patients with liver cancer by sequencing. METHODS: We used next-generation targeted sequencing technology to identify mutations in patients with liver cancer. The ctDNA from 10 patients with hepatocellular carcinoma (including eight cases of primary hepatocellular carcinoma and two cases of secondary hepatocellular carcinoma) was sequenced. We used SAMtools to detect and screen single nucleotide polymorphisms (SNPs) and insertion deletion mutations (INDELs) and ANNOVAR to annotate the structure and function of the detected mutations. Screening of pathogenic and possible pathogenic genes was performed using American College of Medical Genetics and Genomics (ACMG) guidelines. GO analysis and KEGG analysis of pathogenic and possible pathogenic genes were performed using the DAVID database, and protein–protein interaction network analysis of pathogenic and possible pathogenic genes was performed using the STRING database. Then, the Kaplan–Meier plotter database, GEPIA database and HPA database were used to analyse the relationship between pathogenic and possible pathogenic genes and patients with liver cancer. RESULTS: Targeted capture and deep sequencing of 560 cancer-related genes in 10 liver cancer ctDNA samples revealed 8,950 single nucleotide variation (SNV) mutations and 70 INDELS. The most commonly mutated gene was PDE4DIP, followed by SYNE1, KMT2C, PKHD1 and FN1. We compared these results to the COSMIC database and determined that ctDNA could be used for sequencing. According to the ACMG guidelines, we identified 54 pathogenic and possible pathogenic mutations in 39 genes in exons and splice regions of 10 HCC patients and performed GO analysis, KEGG analysis, and PPI network analysis. Through further analysis, four genes significantly related to the prognosis of liver cancer were identified. CONCLUSION: In this study, our findings indicate that ctDNA can be used for sequencing. Our results provide some molecular data for the mapping of genetic variation in Chinese patients with liver cancer, which enriches the understanding of HCC pathogenesis and provides new ideas for the diagnosis and prognosis of HCC patients. |
format | Online Article Text |
id | pubmed-9121877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91218772022-05-21 The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma Ding, Yubo Yao, Jingwei Wen, Meiling Liu, Xiong Huang, Jialu Zhang, Minghui Zhang, Yu Lv, Yufan Xie, Zhuoyi Zuo, JianHong PeerJ Bioinformatics BACKGROUND: The genome map of hepatocellular carcinoma (HCC) is complex. In order to explore whether circulating tumor cell DNA (ctDNA) can be used as the basis for sequencing and use ctDNA to find tumor related biomarkers, we analyzed the mutant genes of ctDNA in patients with liver cancer by sequencing. METHODS: We used next-generation targeted sequencing technology to identify mutations in patients with liver cancer. The ctDNA from 10 patients with hepatocellular carcinoma (including eight cases of primary hepatocellular carcinoma and two cases of secondary hepatocellular carcinoma) was sequenced. We used SAMtools to detect and screen single nucleotide polymorphisms (SNPs) and insertion deletion mutations (INDELs) and ANNOVAR to annotate the structure and function of the detected mutations. Screening of pathogenic and possible pathogenic genes was performed using American College of Medical Genetics and Genomics (ACMG) guidelines. GO analysis and KEGG analysis of pathogenic and possible pathogenic genes were performed using the DAVID database, and protein–protein interaction network analysis of pathogenic and possible pathogenic genes was performed using the STRING database. Then, the Kaplan–Meier plotter database, GEPIA database and HPA database were used to analyse the relationship between pathogenic and possible pathogenic genes and patients with liver cancer. RESULTS: Targeted capture and deep sequencing of 560 cancer-related genes in 10 liver cancer ctDNA samples revealed 8,950 single nucleotide variation (SNV) mutations and 70 INDELS. The most commonly mutated gene was PDE4DIP, followed by SYNE1, KMT2C, PKHD1 and FN1. We compared these results to the COSMIC database and determined that ctDNA could be used for sequencing. According to the ACMG guidelines, we identified 54 pathogenic and possible pathogenic mutations in 39 genes in exons and splice regions of 10 HCC patients and performed GO analysis, KEGG analysis, and PPI network analysis. Through further analysis, four genes significantly related to the prognosis of liver cancer were identified. CONCLUSION: In this study, our findings indicate that ctDNA can be used for sequencing. Our results provide some molecular data for the mapping of genetic variation in Chinese patients with liver cancer, which enriches the understanding of HCC pathogenesis and provides new ideas for the diagnosis and prognosis of HCC patients. PeerJ Inc. 2022-05-17 /pmc/articles/PMC9121877/ /pubmed/35602894 http://dx.doi.org/10.7717/peerj.13473 Text en ©2022 Ding et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Bioinformatics Ding, Yubo Yao, Jingwei Wen, Meiling Liu, Xiong Huang, Jialu Zhang, Minghui Zhang, Yu Lv, Yufan Xie, Zhuoyi Zuo, JianHong The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma |
title | The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma |
title_full | The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma |
title_fullStr | The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma |
title_full_unstemmed | The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma |
title_short | The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma |
title_sort | potential, analysis and prospect of ctdna sequencing in hepatocellular carcinoma |
topic | Bioinformatics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121877/ https://www.ncbi.nlm.nih.gov/pubmed/35602894 http://dx.doi.org/10.7717/peerj.13473 |
work_keys_str_mv | AT dingyubo thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT yaojingwei thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT wenmeiling thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT liuxiong thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT huangjialu thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT zhangminghui thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT zhangyu thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT lvyufan thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT xiezhuoyi thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT zuojianhong thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT dingyubo potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT yaojingwei potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT wenmeiling potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT liuxiong potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT huangjialu potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT zhangminghui potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT zhangyu potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT lvyufan potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT xiezhuoyi potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma AT zuojianhong potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma |